Women’s Health Consultant
Strategic Women’s Health Consulting for Healthcare, Biotech & Innovation Organisations
Helping organisations navigate the rapidly evolving women’s health landscape through evidence-based strategy, healthcare innovation, research translation, and commercial insight.
Strategic Consulting for Women’s Health & Healthcare Innovation
Women’s health is one of the fastest-growing areas of healthcare innovation, yet many organisations face challenges translating scientific advances into meaningful clinical, commercial, and societal impact.
Dr Lana McClements is an internationally recognised women’s health leader, clinical pharmacist, researcher, and innovation strategist with more than 20 years of experience spanning healthcare, biomedical technology, translational research, and industry collaboration.
Working at the intersection of science, healthcare, and innovation, Lana helps organisations identify opportunities, evaluate emerging technologies, develop evidence-based strategies, and accelerate the translation of research into real-world outcomes.
Her unique combination of clinical expertise, scientific leadership, commercial understanding, and innovation experience enables her to bridge the gap between discovery and implementation.
Lana has advised and collaborated with healthcare organisations, biotech companies, research institutes, government stakeholders, and innovation partners to support strategic decision-making, research translation, commercialisation pathways, and healthcare innovation initiatives.
Areas of Expertise
- Women’s health strategy and innovation
- Healthcare innovation and emerging technologies
- Research translation and commercialisation
- Biotech and MedTech innovation
- Evidence-based healthcare
- Strategic partnerships and stakeholder engagement
- Clinical and translational research
- Leadership, advocacy, and organisational impact
Women’s Health Consulting for Healthcare & Biotech Organisations
Lana works with healthcare organisations, biotechnology companies, pharmaceutical organisations, universities, research institutes, and innovation teams seeking expert guidance in women’s health and biomedical innovation.
Her experience spans collaborations with organisations including Inventia Life Science, TissueGnostics, Almac Discovery, Revvity, Mayo Clinic, INFANT Research Centre, Minomic International, Alcolizer, and Innovatio.
Through these partnerships, she has supported the development, evaluation, and translation of innovative technologies, diagnostics, therapeutics, and healthcare solutions designed to address unmet needs in women’s health.
Lana’s work has received international recognition and has been featured by Nature Reviews Bioengineering, The Conversation, ABC, and 9News, reaching an audience of more than 370 million people globally.
Her achievements include the Heart Foundation Future Leader Fellowship (2022–2026), NSW Health Cardiovascular Research Capacity Program Grant (2026–2029), and the Society for Reproductive Biology Emerging Research Leader Award.
Healthcare Innovation & Research Translation
Lana has led multidisciplinary programs that bridge academia, healthcare, and industry to translate scientific discoveries into clinically meaningful innovations.
Her work has contributed to the development of novel diagnostic technologies, predictive biomarkers, therapeutic strategies, and advanced disease models that improve understanding and management of complex women’s health conditions.
Translational Diagnostics for Preeclampsia
Lana’s research identified and validated novel predictive and diagnostic biomarkers for preeclampsia, leading to the development of a first-in-class point-of-care testing platform designed to support earlier detection and improved clinical decision-making.
Advanced Placental Disease Models
She led the development of the world’s first 3D bioprinted placental organoid models and advanced placenta-on-a-chip technologies, creating clinically relevant platforms for drug screening, biomarker discovery, and disease modelling.
Therapeutic Innovation
Lana’s translational research contributed to the advancement of ALM201, a novel ovarian cancer therapeutic that progressed to Phase I clinical evaluation and received FDA Orphan Drug Designation for ovarian cancer.
These experiences provide a practical understanding of how innovative ideas move from laboratory discovery through validation, regulatory pathways, commercialisation, and ultimately clinical impact.
Consulting Services
Areas of Consulting Support
Women's Health Strategy
Supporting organisations to identify opportunities, assess emerging trends, and develop evidence-based strategies within women’s health.
Healthcare Innovation
Advising on innovation pipelines, technology evaluation, translational pathways, and future healthcare opportunities.
Research Translation
Helping organisations bridge the gap between scientific discovery and practical implementation.
Biotech & MedTech Innovation
Providing scientific and strategic insight into product development, translational research, and commercial positioning.
Leadership & Advocacy
Providing guidance on leadership, strategic influence, diversity, inclusion, and organisational culture.
Stakeholder & Patient Engagement
Supporting patient-centred approaches that improve adoption, communication, and impact.
Industry-Academic Collaboration
Facilitating partnerships that accelerate innovation, funding opportunities, and translational outcomes.
Lana partners with:
Lana partners with:
- Healthcare organisations and health services
- Biotechnology companies
- Pharmaceutical organisations
- FemTech companies and startups
- Universities and research institutions
- Government and policy stakeholders
- Research translation and innovation teams
- Investors and organisations evaluating women’s health technologies
Frequently Ask Questions
Find answers to common questions about Dr. Lana McClements’ women’s health consulting services, engagement process, and areas of expertise.
A women’s health consultant provides expert strategic advice to organisations operating within healthcare, biotechnology, pharmaceuticals, research, and innovation. This may include healthcare strategy, technology assessment, research translation, stakeholder engagement, and innovation planning.
Yes. Lana has extensive experience collaborating with biotechnology, pharmaceutical, diagnostics, and medical technology organisations across research, innovation, and translational projects.
Absolutely. Lana supports organisations seeking to evaluate emerging opportunities, develop innovation strategies, and translate scientific advances into impactful healthcare solutions.
Yes. Consulting support can include project design, translational strategy, stakeholder engagement, partnership development, and scientific advisory services.
Let’s Discuss Your Organisation’s Goals
Whether you’re developing new technologies, evaluating opportunities in women’s health, building innovation strategies, or seeking expert scientific guidance, Lana can help you navigate complexity and accelerate impact.